INDVIndivior Pharmaceuticals, Inc.
# 24 · $34.47 (-2.43%) · $4.07B · Healthcare
Rango 52 semanas
Señales de riesgo alta
El motor de scoring ha marcado estas señales de severidad alta. Son avisos para investigar y no forman parte del score.
- Altman Z in distress zone
Datos de mercado
- P/E
- 12.18
- 1M
- -4.25%
- 1A
- +36.35%
- Rentab.
- —
- RSI
- 41.52
- MACD
- -0.01%
Desglose
Por qué
- P/E of 12.2
- earnings growth of 2900.0% (inflated by an unusually low prior year)
- profit margin of 26.7%
- 12-1 momentum return of 42.4%
- EPS vs. estimates: +41.7% on average
El razonamiento lo genera el motor de scoring (en inglés).
Piotroski F-Score
3
3 / 9 checks superados
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Señales de riesgo
- Altman Z in distress zoneAlta
Z-Score 1.22 (< 1.81) — financial distress risk per the Altman model
- Negative free cash flowMedia
FCF $-0.1B — burning cash
- Earnings quality (accruals)Media
operating cash flow below reported net income — profits not backed by cash
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Rising leverageInfo
debt/assets higher than the previous fiscal year
Análisis de la empresa
Business Overview Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for substance use disorders (SUDs), with core products for opioid use disorder (OUD) including SUBLOCADE (monthly extended‑release buprenorphine injection) and SUBOXONE Film (buprenorphine/naloxone sublingual film), plus OPVEE (nalmefene) nasal spray for opioid overdose reversal. It generates revenue primarily from product sales (predominantly in the U.S., which represented ~85% of net revenue in 2024) through wholesalers/distributors with coverage influenced by third‑party payors. Market Position Indivior is a long-standing addiction-treatment player and a leading branded manufacturer in OUD pharmacotherapy, differentiated by long‑acting injectable treatment (SUBLOCADE) and a recognized branded transmucosal franchise (SUBOXONE). Competitive dynamics are driven by formulary access/rebates, clinician adoption, and the availability of generic and other branded OUD therapies. Key Segments Indivior reports operations primarily by geography, with its principal commercial market in the United States and additional sales in selected rest-of-world markets (e.g., parts of Europe, Canada, Australia) via direct operations and distribution partners.
Resumen generado por IA a partir de datos de terceros; puede contener errores. No constituye asesoramiento financiero ni recomendación de inversión.
Periodo: 2021-12-31 → 2025-12-31
Un guion (—) indica que el dato no está disponible para ese ejercicio, no que sea cero. Aquí no se estima ni se rellena nada.